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Abstract
Prion-related disorders (PrDs) are fatal neurodegenerative disorders characterized by progressive neuronal impairment as
well as the accumulation of an abnormally folded and protease resistant form of the cellular prion protein, termed PrP
RES.
Altered endoplasmic reticulum (ER) homeostasis is associated with the occurrence of neurodegeneration in sporadic,
infectious and familial forms of PrDs. The ER operates as a major intracellular calcium store, playing a crucial role in
pathological events related to neuronal dysfunction and death. Here we investigated the possible impact of PrP misfolding
on ER calcium homeostasis in infectious and familial models of PrDs. Neuro2A cells chronically infected with scrapie prions
showed decreased ER-calcium content that correlated with a stronger upregulation of UPR-inducible chaperones, and a
higher sensitivity to ER stress-induced cell death. Overexpression of the calcium pump SERCA stimulated calcium release
and increased the neurotoxicity observed after exposure of cells to brain-derived infectious PrP
RES. Furthermore, expression
of PrP mutants that cause hereditary Creutzfeldt-Jakob disease or fatal familial insomnia led to accumulation of PrP
RES and
their partial retention at the ER, associated with a drastic decrease of ER calcium content and higher susceptibility to ER
stress. Finally, similar results were observed when a transmembrane form of PrP was expressed, which is proposed as a
neurotoxic intermediate. Our results suggest that alterations in calcium homeostasis and increased susceptibility to ER
stress are common pathological features of both infectious and familial PrD models.
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Introduction
Most neurodegenerative disorders, including amyotrophic
lateral sclerosis, Alzheimer’s, Parkinson’s, Huntington’s disease,
and Prion-related disorders (PrDs), share common pathology
features, highlighted by the accumulation of abnormal protein
aggregates containing disease-specific misfolded proteins [1].
PrDs, also known as transmissible spongiform encephalopathies,
are fatal neurodegenerative diseases affecting humans and other
animals. Primary symptoms include rapid and progressive
dementia, and ataxia [2]. Prion diseases are characterized by the
spongiform degeneration of the brain accompanied by the
accumulation of a misfolded and protease-resistant form of the
cellular prion protein (PrP
C), termed PrP
RES [2,3]. The etiology of
PrDs can be divided into three categories including hereditary,
sporadic and infectious forms. Familial prion diseases, including
Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), and
Gerstmann-Stra ¨ussler-Scheinker syndrome (GSS), are all linked to
mutations in the gene encoding PrP
C, PRNP, where at least 20
different mutations which trigger PrP misfolding and the
generation of different levels and conformers of PrP
RES [2].
Infectious PrDs have an unusual mechanism of transmission and
include scrapie in goat and sheep, chronic wasting disease in elk and
deer, and bovine spongiform encephalopathy in cattle. The
‘‘protein-only’’ hypothesis postulates that infectious prion patho-
genicity results from a conformational change of natively folded
PrP
C from its primarily a-helical structure to an insoluble b sheet
conformation, initiated by a direct interaction with PrP
RES present
in the infectious agent. Then, PrP misfolding replicates in a cyclic
manner where newly generated PrP
RES catalyzes the generation of
more pathological prions at the expense of endogenous PrP
C [2,4].
Like other secretory proteins, PrP
C undergoes extensive post-
translational processing in the endoplasmic reticulum (ER) and
Golgi [5]. After trafficking through the secretory pathway, fully
matured PrP
C localizes to cholesterol-rich lipid rafts, and cycles
through the endocytic pathway (review in [5]). During the folding
process at the ER, around 10% of PrP
C is naturally misfolded and
eliminated by the proteasome through the ER-associated degra-
dation (ERAD) pathway [6]. The rate of ERAD-mediated
degradation is substantially increased for familial PrP mutant
forms [7,8,9,10,11]. Upon synthesis, most familial mutant PrP
variants are retained and aggregated in the ER and Golgi, where
they may exert their pathological effects (review in [12]). For
instance, the neurotoxic mutants PrP
D178N/Met129, linked to FFI,
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PG14 (nine-octapeptide insertion), linked to CJD, are
partially retained in their transit through the secretory pathway
[13]. The mutant PrP
Q217R linked to GSS is also retained at the
ER and strongly interacts with the ER chaperone BiP/Grp78
[7,14]. In addition, the experimental point mutation PrP
L9R/3AV,
leads to expression of an abnormal form of PrP called PrP
CTM,
exclusively located at the ER/Golgi as a transmembrane protein
[9,15,16,17]. PrP
CTM is proposed to be an intermediate species in
PrP
RES formation, mediating prion neurotoxicity. In contrast to
familial PrDs, the generation of infectious PrP
RES is proposed to
occur at the plasma membrane and during its cycling through the
endocytic pathway [18,19,20]. However, many studies in
infectious PrDs models have shown the trafficking and accumu-
lation of PrP
RES at the ER and cytosol [21,22,23,24,25,26,27].
Although the mechanism of PrP
RES pathogenesis is still highly
controversial, accumulating data suggests that perturbations in ER
homeostasismaycontribute toneurodegeneration inPrDs. ERstress
is triggered by a number of conditions that interfere with oxidative
protein folding processes in the ER which lead to accumulation of
intralumenal misfolded proteins (reviewed in [28]). The unfolded
protein response (UPR) is an integrated signal transduction pathway
activated by ER stress that transduces information about the protein
folding status in its lumen to the cytosol and nucleus to increase
protein folding capacity and decrease unfolded protein load [28].
Conversely, under chronic ER stress cells undergo apoptosis [29].
Chronic ER stress is associated with the pathogenicity of several
neurodegenerative diseases linked to protein misfolding [1].
Upregulation of UPR-responsive chaperones, such as Grp78/BiP,
Grp94, and Grp58/ERp57, and other ER stress markers is observed
in the brain of patients affected with sporadic and new variant CJD
[30,31] and in different mouse models of scrapie [22,30,32,33,
34,35]. Besides, a recent report suggests that the expression of a
GSS-linked PrP mutant triggersERstressinacellularmodel [36].In
addition, ER stress conditions induce PrP
C aggregation in neuronal
cultures [29,37] and in yeast models of PrD [38]. In vitro studies
revealed that PrP
RES purified from the brainof scrapie-infected mice
[30] or synthetic PrP-derived peptides induces ER stress [39,40].
However, a direct link between PrP
RES and perturbations of ER
homeostasis is still missing.
Different conditions alter the protein folding process at the ER
lumen. Among them, sustained calcium release from the ER has
been shown to affect the normal function of different ER-resident
chaperones (review in [41,42]). Suboptimal activity of ER
chaperones triggers stress due to deficiency of protein folding,
activating the UPR [43]. This mechanism has been recently
proposed to operate in diseases such as lysosomal storage disorders
and diabetes [44,45]. It has been suggested that brain-derived
infectious PrP
RES [30] and synthetic PrP peptides may affect
calcium homeostasis [46,47,48,49,50,51], but its possible contri-
bution to PrP
RES neurotoxicity and ER stress has not been
addressed directly. Here we have evaluated the possible impact of
PrP
RES on ER stress responses and calcium homeostasis using both
acute and chronic models of infectious PrDs, in addition to two
familial PrDs models. Our data suggest that alteration of ER
calcium homeostasis is a common and key neuropathological
event in different models of PrDs, playing an important role in
neurodegeneration.
Results
Cells chronically infected with RML scrapie prions are
more susceptible to ER stress
To study the impact of prion replication in the physiology of the
ER, we stably infected Neuro2a cells with the Rocky Mountain
Laboratory (RML) scrapie strain, (here termed N2a-RML). To
avoid selection effects, a clonal line was derived from Neuro2A to
perform all experiments on an isogenic background. PrP
RES
replication at expenses of endogenous PrP
C was stable for several
weeks in culture (.8 weeks) as confirmed by dot blot detection of
proteinase K (PK)-resistant PrP (Figure 1A). To test the effect of
PrP
RES replication on the susceptibility of cells to ER stress, we
treated control and N2a-RML cells with the ER stress-inducing
agent A23187 (a calcium ionophore) and then monitored cell
viability with two different assays. Although the infection of cells
with RML scrapie prions did not induce evident spontaneous cell
death of cell cultures (not shown), the exposure of N2a-RML cells
to nanomolar concentrations of A23187 led to enhanced cell death
when compared to non-infected cells (Figure 1B, left panel).
Analysis of nuclear morphology after Hoechst staining confirmed
the appearance of apoptotic nuclei in cells treated with A23187,
which was enhanced in N2a-RML cells (Figure 1B, right panel).
To confirm these results, we induced ER stress with tunicamycin (a
N-linked glycosylation inhibitor) or thapsigargin (an inhibitor of
ER-calcium ATPase, SERCA). Treatment of cells with both drugs
lead to enhanced susceptibility to ER stress in N2a-RML cells
when compared to non-infected cells (Figure 1C and D). Similar
results were obtained when a different clone of Neuro2A was
infected with RML prions and the phenotypes were not affected
by cell passages (not shown). These effects were not observed when
calphostine (Figure 1E) or staurosporine (not shown) were used to
trigger intrinsic-cell death programs that are independent of ER
stress. As an additional control, we selected a Neuro2a clone that
was resistant to replicate scrapie prions (Neuro2a-RML-Ins). We
exposed Neuro2a-RML-Ins cells to RML prions and then assessed
their susceptibility to ER stress. Comparison of this cell line with
N2a-RML cells confirmed the requirement of sustained prion
replication to enhance the rate of ER stress-mediated cell death
(Figure S1A).
To explore further the impact of prion replication on the
susceptibility to ER stress, we monitored the levels of UPR
activation in N2a-RML and control cells after exposure to
tunicamycin. Analysis of Grp94, Grp78/BiP and Grp58/ERp57
levels revealed a stronger ER stress response in N2a-RML cells
over time when compared to non-infected cells, manifested by a
marked increase in the expression of these three ER stress-
responsive chaperones (Figure 1F). No differential effects on total
levels of PrP or its de-glycosylation upon tunicamycin treatment
were observed in N2a-RML when compared to control cells,
indicating that this compound was equally effective in both cell
cultures (Figure 1G). We also monitored pro-caspase-12 process-
ing, another marker of ER stress [52]. We observed an
enhancement in the rate of pro-caspase-12 processing in N2a-
RML cells undergoing ER stress compared to non-infected cells
(Figure 1H). We were not able to detect the active fragments of
caspase-12 in Neuro2a using three different antibodies, suggesting
that the protein is unstable. To validate the functional role of
caspase-12 in our experimental system, we expressed a dominant
negative form of caspase-12 in Neuro2a cells and then assessed
their susceptibility to ER stress (Figure S1B). Taken together, our
results indicate that prion replication sensitized Neuro2a cells to
ER-related injuries, suggesting that PrP
RES disturbs the homeo-
stasis of this organelle.
Prion replication affects ER calcium homeostasis
Based on the known connection between ER stress and
perturbation of calcium homeostasis, we next explored the relative
ER calcium content in N2a-RML cells. We monitored the passive
release of calcium from the ER by inhibiting the SERCA pump
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RES replication sensitizes Neuro2a cells to ER stress-mediated cell death. (A) Neuro2a cells were infected with RML-scrapie
brain homogenate (N2a-RML) or uninfected (N2a). Prion replication in stable cultures was determined by PK treatment and dot blot analysis after 2
weeks of infection. (B) Left panel: N2a-RML and control cells were treated with different concentrations of A23187 for 48 h and cell viability was
determined by MTS assay. Right panel: in parallel, Neuro2a cells were treated with 90 nM of the Ca
2+ ionophore A23187, and after 48 h incubation
apoptotic nuclear morphology was visualized after Hoechst dye staining. Infected and control cells were also subjected to treatments with indicated
concentrations of tunicamycin (C), or thapsigargin (D), and after 48 h cell viability was quantified with the MTS assay. In panels B–D the mean and
standard deviation from three independent experiments is shown. (E) As controls, cells were treated with different concentrations of calphostine for
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passive release figure S1C). All experiments were performed in the
absence of extracellular calcium to specifically assess the
contribution of intracellular calcium stores to cytosolic calcium
signals. As shown in Figure 2A, N2a-RML cells presented
diminished ER calcium release after thapsigargin treatment,
which was dose-dependent (Figure 2B). As control, cells were
pre-treated with thapsigargin for 30 min and then stimulated with
A23187 in the absence of extracellular calcium, observed a
dramatic attenuation of the release of calcium from the ER by
thapsigargin tretament (not shown). These results suggest that
prion replication affects ER calcium homeostasis. Based on these
results, we then analyzed the subcelular distribution of PrP in N2a
control and N2a-RML cells by subcellular fractionation using
sucrose gradients. As previously described [21] an increased
accumulation of PrP was observed at ER fractions (PDI positive)
when cells were chronically infected with RML scrapie prions
(Figure S2).
SERCA overexpression sensitizes cells to acute exposure
to infectious PrP
RES
We then addressed the possible role of ER stress and calcium
homeostasis disturbance on an acute model of infectious PrDs. In
this model cells were exposed to highly purified preparations of
PrP
RES derived from brains of 139A scrapie-infected mice at the
symptomatic stage (Figure S3A–C). Treatment of cells with brain-
derived PrP
RES led to a significant induction of Grp58, Grp78 and
Grp94 (Figure 3A), indicating the occurrence of ER stress. As
positive control, cells were treated with brefeldin A. Using this
system, incorporation of PrP to the cells was observed over time as
monitored by Western blot in total protein extracts (Figure S3D).
To further define a possible role of calcium in prion neurotoxicity
we modulated ER calcium content by overexpressing SERCA, as
previously described [53,54]. We generated cell lines stably
expressing SERCA and selected two lines for the analysis
(Figure 3B). The levels of SERCA expression correlated well with
the amount of calcium released from the ER after treatment with
A23187 (Figure 3C), arachidonic acid or thapsigargin (not shown),
indicating that this strategy has a functional effect on ER calcium
metabolism in this cellular model. We then addressed the
susceptibility of SERCA overexpressing cells. Using this acute
model, purified PrP
RES led to significant cell death after 48 h of
treatment in a dose-dependent manner using concentrations in the
nanomolar range (Figure 3D). SERCA overexpressing cells were
highly susceptible to PrP
RES-induced cell death compared to
control cells (Figure 3D).
The ER contains mainly two types of calcium channels, the
inositol 1,4,5-triphosphate receptors (IP3Rs) and ryanodine
receptors (RyRs) [55], which regulate the release of calcium into
the cytoplasm. To study the possible contribution of these channels
to PrP
RES-induced calcium release, we pre-treated Neuro2a cells
with xestospongin C or ryanodine, two known IP3Rs and RyRs
inhibitors, respectively. Treatment of cells with these inhibitors
decreased the cytosolic calcium increase after treatment of cells
with brain-derived PrP
RES (Figure 3E). Unfortunately, it was not
possible to study the effects of ER channel inhibitors on PrP
RES
cytotoxicity because both compounds were highly toxic to
Neuro2A cells after prolonged incubation (.24 h, data not show).
This acute treatment may represent an additional contribution of
cytosolic calcium to PrP
RES neurotocxicity due to mitochondrial
calcium overload as suggested in models where cells were treated
with micro molar concentrations of PrP peptides [40]. However,
this acute experimental setting offers a useful measure of the
impact of PrP
RES to ER calcium release by monitoring short term
Figure 2. Altered calcium homeostasis in scrapie-infected cells.
(A) N2a-RML and non-infected cells were loaded with the cytosolic
calcium dye Fluo-4 and changes in fluorescence intensity were
measured over time after addition of 4 mM thapsigargin using the
FLIPR1 setup. Data represents the average of three independent
experiments. (B) Calcium responses were analyzed after treatment with
different concentrations of thapsigargin. Fluorescence levels after
10 min of treatment are shown. Mean and standard deviation is
presented. Student t-test was used to analyze statistical significance
(** p,0.01, * p,0.05). All determinations in panels A and B were made
in the absence of extracellular calcium.
doi:10.1371/journal.pone.0015658.g002
48 h, and cell viability was quantified by MTS analysis. (F) N2a-RML and control cells were treated with 20 mg/ml tunicamycin for 30 h, and the
expression levels of Grp58, Grp78, and Grp94 were analyzed by Western blot. Three different independent treatments are presented. Actin levels
were determined as loading control. Right panel: Quantification of the relative induction levels is presented and normalized with the value obtained
in non-treated cells. Mean and standard deviation is presented. Student t-test was used to analyze statistical significance (** p,0.001, * p,0.05).
(G) N2a-RML and control cells were treated with 20 mg/ml tunicamycin for indicated time points, and the expression levels of PrP were analyzed by
Western blot. Non- glycosylated and glycosylated PrP forms are indicated. (H) N2a-RML cells and control N2a cells were treated with tunicamycin and
the levels of pro-caspase-12 processing were determined by Western blot. As controls, the levels of actin are shown. The pro-caspase-12 expression
levels were quantified and the ratio between the expression levels of treated and control Cells is presented at the bottom of the gels.
doi:10.1371/journal.pone.0015658.g001
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RES from scrapie-infected brains. (A) Neuro2a cells were treated
for 27 h with brain derived PrP
RES (50 nM) or brefeldin A (12 mM), and the levels of Grp58, Grp78, and Grp94 were determined by Western blot. Three
independent experiments are presented. Actin levels were monitored as loading control. Right panel: The protein band intensities were quantified
and normalized with the expression of actin and the fold induction is presented in comparison with the average signal of non-treated cells. Values
correspond to the mean and standard deviation. Student t-test was used to analyze statistical significance with control non-treated cells (** p,0.01,
* p,0.05) (B) Neuro2a cells were stably transfected with an expression vector for SERCA, and its expression levels were determined by Western blot
analysis. Two different cell clones and a control line transfected with empty pcDNA3.1 vector (Mock) are presented. (C) As control, the cell lines
described in (A) were loaded with Fluo-4, and the release of ER calcium was monitored over time after addition of 300 nM A23187 (arrow) in the
absence of extracellular calcium. Arbitrary units of fluorescence are shown (AU). (D) Cell lines expressing different amounts of SERCA pump and the
control cell line (Mock) were treated with indicated concentrations of purified PrP
RES from 139A-scrapie infected brains. After 48 h of incubation, cell
viability was analyzed with the MTS assay. Data represent mean and standard deviation of three experiments. p values were calculated with
parametric t-test (E) Neuro2a cells were loaded with Fluo-4 and then pre-incubated with 10 mM ryanodine or 10 mM xestospongin C for 2 hours or
left untreated. Calcium fluorescence was measured after 5 min of the addition of 200 nM of purified PrP
RES. All determinations were performed in the
absence of extracellular calcium. Data represent mean and standard deviation of three determinations. Student t-test was used to analyze statistical
significance with control non-treated cells (* p,0.05).
doi:10.1371/journal.pone.0015658.g003
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PrP
RES alters ER calcium homeostasis.
Expression of PrP mutants linked to CJD and FFI increase
the susceptibility of cells to ER stress
To investigate the role of ER stress in familial forms of PrD, we
expressed two PrP mutant forms in Neuro2a cells, PrP
PG14 and
PrP
D177N/Met128, which are linked to familial CJD and FFI
respectively [2,56]. In addition, we employed the neurotoxic
mutant PrP
CTM. We transiently transfected expression vectors for
these PrP mutants and PrP
C as a control using EGFP fusion
proteins, and then visualized their subcellular distribution by
confocal microscopy and resistance to PK. As predicted, PrP
C was
mainly located at the plasma membrane (Figure 4A and B). We
also confirmed the partial retention of PrP
D177N and PrP
PG14 at
the ER after co-expression of PrP with the ER marker KDEL-
dsRED (Figure 4A and B). Similarly, PrP
CTM predominantly
accumulated at the ER (Figure 4A) and Golgi in our experimental
system (co-stained with anti-GM130 antibodies, not shown). To
monitor the possible generation of PrP
RES, we transiently
expressed 3F4-epitope tagged mutants in 293T cells. The addition
of a 3F4 tag allowed us specifically detecting overexpressed PrP
and not the endogenous protein. Total protein extracts were
treated with two concentrations of PK and analyzed by Western
blot. As shown in Figure 4C, expression of the PrP mutants lead to
significant accumulation of PK-resistant PrP species. PrP
D177N
displayed higher expression and increased PK-resistance
(Figure 4C). Changes in the electrophoresis pattern of the mutants
were observed as previously described [13,16], corresponding to
changes in the glycosylation pattern for PrP
CTM and PrP
D177N,o r
a higher molecular weight for PrP
PG14 due to the insertional
mutation. After characterizing our cellular model, we generated
Neuro2a cell lines stably expressing PrP
C or the three PrD-related
mutants. Exposure of these cell lines to tunicamycin revealed that
the expression of PrP
D177N increased the susceptibility to ER
stress-induced cell death (Figure 4D). Expression of PrP
CTM or
PrP
PG14 expressing cells showed an intermediate phenotype,
slightly enhancing their susceptibility to lower concentrations of
tunicamycin treatment (Figure 4D). Treating PrP
D177N expressing
cells with thapsigargin also confirmed an enhanced susceptibility
to ER stress (Figure 4E). The changes in cell viability were small
for PrP
CTM or PrP
PG14 possibly because the stable selection of
these neurotoxic mutants may lead to the elimination of a
subpopulation of cells that are more susceptible to the pathological
effects of the PrP mutants. In fact, the transient transfection of PrP
mutants lead to ,40% of cell death after 72 h of transfection as
monitored by the MTS assay (not shown). Moreover, when we
analyzed the levels of the different PrP constructs over time, we
observed a decreased expression of PrP
CTM or PrP
PG14 after stable
selection, whereas higher PrP
D177N expression levels were
maintained over time (Figure S4). Thus, these results suggest that
PrP mutants related to familial PrDs, in addition to PrP
CTM, alters
the homeostasis of the ER to different extents, increasing the
susceptibility to ER stress.
Expression of mutant PrP forms alters ER calcium
homeostasis
To address the possible impact of familial PrD mutant PrP on
ER calcium homeostasis, we measured the relative ER calcium
content in cells stably expressing three PrP mutants or wild type
PrP
C after thapsigargin treatment in the absence of extracellular
calcium. Treatment of Neuro2a cells expressing PrP
CTM or
PrP
D177N with 10 mM thapsigargin led to a decreased release of
ER calcium toward the cytosol compared to control PrP
C
expressing cells (Figure 5A and B). Similar results were observed
when cells were exposed to higher thapsigargin concentrations
(40 mM; Figure 5C and D). These results were also recapitulated in
cells expressing the PrP
PG14 mutant (Figure 5C and D).
To further confirm that cells expressing mutant PrPs have
alterations in ER homeostasis, we studied the effect of other ER
calcium agonists. Treatment of PrP
CTM, PrP
D177N, or PrP
PG14
expressing cells with A23187 in absence of extracellular calcium
showed a substantial decrease on ER calcium release as compared
with PrP
C expressing cells (Figure 5E). Similarly, treatment of all
mutant expressing cells with arachidonic acid (Figure 1F), which
induces IP3R-mediated calcium release, led to a lower cytosolic
calcium increase. Together these results suggest that accumulation
of PrP
RES at the ER in familial PrD models results in decreased
ER calcium content.
Discussion
The protein folding capacity of the ER is directly affected by
different environmental factors including the redox status of the
cell, ER calcium content and ATP levels. ER stress responses are
observed in PrD models, and in human post mortem brain
samples from patients affected with sporadic and new variant CJD
[30,31,32,33,34,35,36,39]. Remarkably, chronic ER stress is
observed in many pathological conditions affecting the nervous
system where the disease is etiologically linked to protein
misfolding and abnormal protein aggregation [1].
The cellular events involved in perturbations of ER homeostasis
in PrDs are not well understood. The main issue is rooted in the
fact that prion replication mostly occurs at the plasma membrane
(in lipids rafts) and during its trafficking and recycling through the
endosomal pathway [5]. In addition, the majority of misfolded PrP
in infectious PrD models accumulates in the brain extracellular
space. Interestingly, different groups have shown that PrP
RES is
also observed in intracellular compartments, where it could be
poly-ubiquitinated and accumulated into cytosolic aggresomes and
autophagosomes [25,26]. In addition, there is evidence that PrP
trafficking from the Golgi to the ER also contributes to the
generation of PrP
RES in scrapie-infected cells [21]. We have
reported the co-inmunoprecipitation of PrP
RES with ER-resident
chaperones in scrapie-infected cells [34], suggesting that a
subpopulation of infectious PrP
RES may actually target the ER
lumen. Moreover, several studies have described the accumulation
of mutant PrP molecules associated with hereditary PrDs at the
ER and Golgi [7,10,11,14,15,16], suggesting that some prion
mutants may exert their pathological effects by affecting these
organelles. Alternatively, different observations suggest that
extracellular PrP
RES may lead to activation of intracellular
signaling pathways that could indirectly impact the ER homeo-
stasis and contribute to neuronal dysfunction [12]. However, the
actual mechanism mediating PrP neurotoxicity in PrDs is not well
understood.
In the present study we investigated the possible contribution of
ER perturbations to prion pathogenesis in distinct PrD models
resembling infectious and familial forms of the disease. Our data
indicates that PrP misfolding leads to a higher susceptibility to ER
stress and abnormal ER calcium homeostasis in chronically
infected scrapie cells and in cells expressing PrP mutant forms
associated with FFI and familial CJD. Similar results were
observed when the neurotoxic mutant PrP
CTM was expressed in
Neuro2a cells. In addition, we studied the impact of PrP
RES on
calcium homeostasis using an acute PrD infectious model where
exogenous PrP
RES was added to the cells at nanomolar
Prion Misfolding Perturbs ER Homeostasis
PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e15658Figure 4. PrP mutants linked to familial PrDs are retained at the ER and increase the susceptibility of cells to ER stress. (A) EGFP
fusion with PrP
C or the PrP mutants PrP
CTM, PrP
D177, and PrP
PG14 were transiently expressed in Neuro2a cells. After 48 h, the subcellular localization of
PrP (green) was visualized using confocal microscopy and co-localized with the ER-marker KDEL-dsRED (red). In addition the nucleus was stained with
Hoechst (blue). (B) A higher magnification of cells analyzed under the same conditions described in panel A is presented. (C) To monitor PrP
RES levels,
Neuro2a cells were transiently transfected with expression vectors for 3F4-tagged versions of PrP
C and mutant PrP. After 48 h, cell extracts were
treated with indicated concentrations of proteinase K (PK) analyzed by Western blot. Hsp90 levels were monitored as loading control. (D) Neuro2a
cells were stably transfected with expression vectors for 3F4-tag versions of PrP
C, PrP
CTM, PrP
D177, and PrP
PG14. Cells were grown in cell culture media
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impact of ER calcium by monitoring cell toxicity after expression
of the ER calcium pump SERCA. In this acute setting, it is
predicted that drastic and fast changes in cytosolic calcium will
lead to mitochondrial calcium overload and apoptosis. In a
chronic conditions, this release of calcium may occur slowly (i.e. in
scrapie infected cells or neurons expressing familial PrP mutants),
generating in the long term a decrease in the ER steady state
calcium levels and ER stress. It may be feasibly that both cytosolic
increased of calcium together with decreased steady state ER
calcium content may synergise in the toxicity of misfolded PrP.
We speculate that a progressive and sustained release of ER
calcium in neurons expressing misfolded PrP species may affect the
protein folding status in this organelle, leading to basal ER stress,
resulting in organelle failure and neuronal dysfunction. At the
same time, increased levels of calcium in the cytoplasm may
perturb several signaling pathways implicated in controlling
neuronal function and survival. Indeed, our recent results suggest
that PrP
RES formation leads to an hyperactivation of the calcium-
dependent phosphatase calcineurin in vivo, leading to dephosphor-
ylation of CREB and BAD [58]. Strikingly, treatment of prion
infected mice at the clinical phase of the disease with the FDA-
approved calcineurin inhibitor FK506 reduced neurodegenera-
tion, leading to improvement on behavioral alterations and
increase animal survival [58], suggesting a functional role of
calcium in synaptic dysfunction and neuronal death.
The ER is a primary compartment for PrP
C folding and also
plays a crucial role in the generation of pathogenic PrP protein
conformations in familial PrDs. Therefore, it is essential to
understand the folding pathways of PrP
C because this information
may give clues about the mechanism underlying sporadic forms of
CJD (the most common PrD in humans) where alteration in the
folding/quality control process or the ER environment may be a
key event in initiating the pathology. In support of this hypothesis,
post-mortem studies of sporadic and new variant CJD brain
samples demonstrated upregulation of ER stress-inducible foldases
[5,30,31]. Several studies indicate that alterations of the ER
homeostasis or inhibition of the proteasome, which blocks ERAD
of misfolded PrP
C, lead to accumulation of abnormally folded
PrP
C that is partially resistant to proteases and insoluble in non-
denaturing detergents [6,22,27,37,57]. These findings together
with the results described in the current study suggest that ER
factors and/or the ER environment, including ER calcium
concentrations, are key determinants of PrP misfolding and the
generation of neurotoxic species. The early signaling events
mediating ER calcium abnormalities by the accumulation of
PrP
RES remain to be determined. Interactions between misfolded
PrP and the proteins modulating calcium transport (i.e. SERCA,
IP3Rs and/or RyRs) may explain part of these phenotypes as
suggested in Huntington’s disease models [59,60]. The findings
presented here may also contribute to a better understanding of
the pathogenesis of other diseases affecting the nervous system
related to protein misfolding and ER stress.
Materials and Methods
Materials
Tunicamycin, A23187, thapsigargin, calphostine, xestospongin
C, and ryanodine were purchased from Calbiochem EMB
Bioscience Inc. (Darmstadt, Germany). Cell medium, fetal calf
serum and antibiotics were obtained from Life Technologies
(Maryland, USA). Arachidonic acid and dantrolene were obtained
from Sigma (Basel, Switzerland). Fluo-4 was purchased from
Molecular Probes. Superfect and plasmid purification kits were
pursed from Qiagene (HiSpeed Plasmid Midi Kit).
Cell culture and viability assays
Neuro2A cells were obtained from ATCC and were cultured in
DMEM supplemented with 10% fetal calf serum and antibiotics
(109000 U/ml Penicillin, 10 mg/ml streptomycin), at 37uC and
5% CO2. For cell viability analysis, cells were grown in collagen IV
coated 96-well plates for 24 h in cell culture medium in 1% serum
before addition of the agonist. Cell viability was quantified using 3-
(4, 5-dimethylthazol-2-yl)-5-3-carboxymethoxy-phenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium (MTS) according to the recommendations
of the supplier (Promega, CellTiter96H Aqueous, Madison, WI). In
addition, cellular death by apoptosis was quantified by nuclear
staining with Hoechst33342.
PrP
RES purification from the brain of scrapie infected
mice.
PrP
RES was purified from mice infected with 139A scrapie as
previously described [61]. Experimental animal protocols for
animal use has been reviewed and approved by the Institutional
Review Board’s Animal Care and Use Committee of the Faculty of
Medicine of the University of Chile (approved protocol CBA #
0232 FMUCH). Brain tissue (approximately 12 brains per
preparation) was homogenized with a manual potter of 20 ml in
PBS (final concentration 50% weight/volume) containing a
protease inhibitor cocktail. After homogenization, an equivalent
volume of a solution containing 20% salkosyl and 0.05% octanol
was added. The brain extract was incubated for 15 min at room
temperature with constant agitation in a wheel rotor. After this step,
non-disrupted tissue was eliminated by centrifugation at 7.0006g
for 15 min. The supernatant was collected and 1/3 volume of 0.1%
SB3-14 was added to the brain homogenate, mixed and centrifuged
at 50.000 r.p.m. in a Ti60 rotor (Beckman) for 2 h at 4uC. After
centrifugation, the pellets were collected and resuspended by
sonication in 10% NaCl, 0.1% SB3-14. The homogenized pellet
was loaded over a sucrose solution (20% sucrose, 0.1% SB-314) and
centrifuged at 80.000 r.p.m. for 2 h at 4uC in a TL100 rotor
(Beckman). The pellet was collected, washed in PBS and
resuspended by sonication in PBS containing 0.1% SB-314.
Thereafter, samples were treated with PK (50 mg/ml) for 2 h
followed by another sucrose step separation after centrifugation at
80.000 r.p.m. for 2 h. The pellet was washed four times with sterile
PBSandresuspended in400 ml ofPBS bysonication.Afterthis step,
purity was estimated to be higher than 90% as estimated by silver
staining and mass spectrometric analysis. PrP
RES concentration was
estimated by western blot analysis, comparing in the same blot the
signal intensity of different dilutions of the purified protein with
known concentrations of the recombinant mouse PrP
C, purchased
from Prionics Inc (Zurich, Switzerland).
Plasmids and cell transfections
Expression vector containing SERCA from rabbit was kindly
provided by Frederica Del Monte (University of Toronto,
containing 2% serum for 16 h and then exposed to different concentrations of tunicamycin. After 24 h, cell viability was determined with the MTS
assay. Data represent mean and standard deviation of three determinations that are representative of three independent experiments. (E) In parallel,
PrP
C and PrP
D177 expressing cells were treated with indicated concentrations of thapsigargin and analyzed as described in D.
doi:10.1371/journal.pone.0015658.g004
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PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e15658Figure 5. Expression of PrP mutants linked to familial PrDs alters ER calcium homeostasis. (A) Neuro2a cells stably transfected with PrP
C,
PrP
D177N, or PrP
CTM were loaded with Fluo-4 and cytosolic calcium signals were monitored in cells exposed to 10 mM thapsigargin (arrow). All
determinations were performed in the absence of extracellular calcium. A representative experiment is presented. (B) The maximum calcium signal
from the experiment presented in panel A was quantified in a total of three independent experiments and normalized with the values obtained in
PrP
C expressing cells (control). Mean and standard error is shown. (C) Neuro2a cells were stably transfected with PrP
C or PrP
PG14 expression vectors
and calcium signals were monitored as described in panel A after exposure to 40 mM thapsigargin (arrow). (D) The maximum calcium signal from
experiment presented in panel A was quantified in a total of three independent experiments and normalized with the values obtained in PrP
C
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caspase-12 mutant lacking its N-terminal pro-domain (amino
acids 1-94, pC12DN) was provided by R. Rao (California).
Expression vectors of 3F4 tagged PrP mutants (PrP
CTM, PrP
PG14,
and PrP
D177N) and GFP fusion proteins were provided by David
Harris (Washington University). The generation of PrP
C-3F4 and
PrP
C-EGFP constructs was previously described [57]. Co-
localization of PrP with ER was assessed by co-transfection with
pDsRed-ER (Clontech Laboratories, cat. 6982-1). Stably-express-
ing Neuro2a cells were produced by transfection using SuperFect
kit (Qiagene, Valencia, CA) following the manufacturer’s instruc-
tions. After 48 h of transfection, cells were selected using
hygromicin (1.5 mg/ml) or G418 (1.3 mg/ml). Individual clones
of Neuro2a cells expressing different levels of SERCA, were
obtained by limiting dilution as described before [30].
Generation of Neuro2A cells chronically infected with
RML scrapie prions
Neuro2a cells can be infected with PrP
RES although the
response and the stability of the infected cells has proved variable,
suggesting heterogeneity may exist in the original cell line [62,63].
In order to establish a stable chronically infected cell, we separated
the original culture in subclones by limiting dilution. A growing
culture was diluted to a density of 5 cells/ml and 100 ml was
transferred to individual wells of a 96 well plate and cultured for 1
week. The individual cultures were examined microscopically to
determine those wells which contained a single focus of growing
cells. The single cell derived cultures were then transferred to 24
well plates and serially passaged every 3–4 days at 1:15 dilution to
maintain stocks. Single clone cultures were tested for sensitivity to
infection by the RML strain of PrP
RES. To do this, 4 ml of a 10%
late stage infected brain extract was added per well of newly
passaged cells, and the cultures were left for a further 4 days to
reach confluence. Cells were serially passaged thereafter in the
absence of PrP
RES. Tests showed that all trace of the initial
inoculum disappeared by passage 4. At this and later passages
individual cultures were tested for the presence of PrP
RES by dot
blotting as previously described [62].
Measurement of intracellular calcium
For biosecurity reasons, in experiment with RML infected cells
or cells treated with purified PrP
RES, the changes in intracellular
calcium levels were measured using the automatized FLIPR1
machine (Molecular devices, Sunnyvale, CA) by the use of the
fluorescent dye Fluo-4, which shows increased fluorescence at
515–535 nm after calcium binding. 10
5 cells per well were grown
on 96-black wells plate coated with collagen IV for 24 h and
serum was decreased to 1% for a further 24 h. Cells were loaded
with Fluo-4 at a final concentration of 10 mg/mL. After 120 min
of incubation at 37uC, the loaded cells were washed twice with
FLIPR buffer (150 mM NaCl, 5 mM KCl, 1 mM MgCl2,1 0m M
Hepes, 10 mM glucose) in the absence of extracellular calcium
and plates were mounted on the FLIPR1 setup. Fluorescence
emission was quantified every 5 seconds for a total time of 30 min.
The basal fluorescence of the dye was usually determined before
the addition of the samples and was assigned a value of zero. The
agonists and inhibitor were added automatically by the FLIPR1
setup, and were prepared in an independent 96-well plate. To
determine the origin of intracellular calcium, cells were pre-treated
with thapsigargin (5 mM), a ryanodine mix (10 mM) or xestospon-
gin C for 15 min before addition of the agonists.
In experiment with PrP mutants, cells were grown in coverslips
and loaded with Fluo-4 AM (3 mM) for 30 min at room
temperature. Coverslips were mounted in a 1 ml capacity
chamber and washed three times with calcium-free buffer
(150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM Hepes,
10 mM glucose and 5 mM EGTA, pH 7.4). Calcium signals were
recorded using an IX-81 inverted microscope for fluorescence
measurements (DSU, Olympus), equipped with a 150-W xenon
lamp (Olympus MT-20). Fluo-4 fluorescence was excited and
detected with a FITC filter cube, using a 40x/1.4 NA oil
immersion objective. Changes in [Ca
2+]i were measured in a field-
of-view consisting of 15–30 cells. Images were acquired every 5
seconds and analyzed using CellR (Olympus) and NIH ImageJ
software. The mean intensities of small cellular areas of interest
were collected as F(t) and the background intensity was subtracted,
using a same-size region of interest outside the cell, yielding F(t)s.
The final signal was normalized to baseline fluorescence F(0), as
[F(t)s 2 F(0)]/F(0) [64,65].
SDS-PAGE and Western Blot Analysis
Cells were homogenized on ice in RIPA buffer (20 mM Tris
pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% DOC, 0.5% triton X-
100) containing a protease inhibitor cocktail (Roche, Basel,
Germany) as previously described [66]. Protein concentration
was determined by micro-BCA assay (Pierce, Rockford, IL). The
equivalent of 30–50 mg of total protein was generally loaded onto
10% SDS-PAGE minigels (Novex NuPage, Invitrogen Life
Technologies, Basel, Switzerland) and analysed by Western
blotting as described. The following antibodies and dilutions were
used: 6H4 anti-PrP, 1:10,000 (Prionics, Zurich, Switzerland), anti-
Caspase-12, 1:2,000 (Exalpha, Watertown, USA); anti-GRP78/
Bip, anti-Grp58/ERp57 and anti-Grp94 1:2,000 (StressGene, San
Diego, CA); anti-actin, 1:2,000 and Hsp90, 1:3000 (Santa Cruz),
anti-3F4 antibody 1:5000 (Abcam). After incubation with the
primary antibody, membranes were incubated for 1 h at room
temperature with horseradish peroxidase-coupled second antibod-
ies diluted 1:10,000 in washing buffer. After washing, specifically
bound antibodies were detected by enhanced chemiluminescence
assay (Amersham Biosciences, Cardiff, UK).
Subcellular Fractionation
To separate and enrich ER membranes, Neuro2a cells were
homogenized by using a stainless steel ball-bearing homogenizer in
0.25 M sucrose, 10 mM Tris-HCl, pH 7.4, 1 mM magnesium
acetate, and a protease inhibitor mixture in a final concentration
of 1 volume of cell pellet per 5 volumes of homogenizing medium.
Sucrose gradients were performed as described in [21]. 1-ml
fractions were collected from the top of each gradient, assayed for
protein content, and methanol-precipitated. After centrifugation at
14,000 rpm for 20 min, the pellets were resuspended in SDS
loading buffer.
expressing cells (control). Mean and standard error is shown. Similar experiments were performed in cells expressing PrP
D177N, or PrP
CTM.( E)I n
parallel, cells expressing PrP
C, PrP
CTM, PrP
D177N, or PrP
PG14 were exposed to 10 mM A23187., or (F) 15 mM arachidonic acid and analyzed using
conditions described in panel A. The maximum calcium signal from the experiment presented in panel A was quantified in a total of three
independent experiments and normalized with the values obtained in PrP
C expressing cells (control). Mean and standard error is shown. In B, D, E and
F, indicated p values were calculated with parametric t-test.
doi:10.1371/journal.pone.0015658.g005
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Data was analyzed by parametric t-test (two-tailed) and
significance was expressed as follow: * P,0.05; ** P,0.01;
*** P,0.005. For the analysis the program SigmaPlot and
GraphPad were employed.
Supporting Information
Figure S1 Control experiments. (A) Replication of
PrPRES at expenses ofendogenous PrPC is required to
increase the susceptibility to ER stress. Twodifferent
Neuro2a clones were selected by their property to sustain
replication of RMLprions (N2a-RML) or that are resistant to
replication (N2a-RML-Ins). Cell were exposedto RML scrapie
prion and after several weeks in culture, they were treated with 12
mMbrefeldin A (Bref. A) or 40 nM A23187. After 48h cell viability
was monitored using theMTS assay. Mean and standard deviation
is presented of three determinations. (B) Expression of a
caspase-12 dominant negative mutant form protect
against ERstress. Left panel: Neuro2 cells were stably
transfected with empty pCDNA.3 vector oran expression vector
for a caspase-12 dominant negative (C289A) construct. Then,cell
viability was monitored after exposure of cells to 12 mM brefeldin
A or 5 mMthapsigargin for 48h using the MTS assay. Data
represent mean and standarddeviation of three determinations.
Right panel: Expression levels of caspase-12 andactin are
presented as controls. (C) Thapsigargin treatment triggers
passive relatedof ER calcium, not affected by inhibition
of IP3R. Neuro2a cells were loaded withFluo-4 and cytosolic
calcium signals were monitored in cells exposed to 10 mMthapsi-
gargin (arrow). Cells were pretreated or not with 1 mM
Xestospongine B (IP3Rinhibitor) for 1h or 50 mM dantrolen
(RYR inhibitor) for 30 min. All determinations wereperformed in
the absence of extracellular calcium. A representative experiment
ispresented.
(PDF)
Figure S2 Increased accumulation PrP at ER fractions
in Neuro2a cells infectedwith RML scrapie prions. Post-
nuclear cell extracts from Neuro2a control and RMLinfectedcells
were fractionated on a sucrose gradient to separate ER fractions
asdescribed in material and methods. Total proteins present in
fractions of 1 ml wereprecipitated and analyzed by Western blot.
Total PrP levels were monitored in eachfraction. As control to
identify ER-enriched fractions, the distribution of PDI wasassessed
by Western blot.
(PDF)
Figure S3 Purification of PrPRES from 139A-scrapie
infected brains. (A) Schematicrepresentation of the preparation
steps used to purify PrPRES from 139A-scrapieinfected brains
(described in material and methods). (B) Qualitative analysis of
theenrichment on PrPRES during purification procedure. Equiv-
alent samples from differentsteps of the purification process were
analyzed by western blot or by silver staining ofthe total proteins
presented in each sample. Samples were loaded in the followin-
gorder: 1: 10% brain homogenate in PBS. 2: Sarcosyl
solubilization. 3: Sarcosylextraction, pellet. 4: Pellet obtained
after sucrose gradient before PK treatment. 5: Pellet obtained after
sucrose gradient after PK treatment. 6: 500 ng of recombi-
nantPrPC, used as a positive control. (C) Quantification of
PrPRES concentration. Knownamounts of recombinant PrPC
were compared with different dilutions of purified PrPRESby
western blot analysis (left panel). The band intensity was quantified
to estimate theconcentration of PrPRES by comparison to the
values obtained with the calibration curveof recombinant PrPC
(right panel). R2 corresponds to the linear regression coefficient.
(D) Neuro2a cells were treated with 1 mg/ml brain derived
PrPRES for indicated timepoints and then washed extensively
with PBS. Then cells were collected bytripsinization and further
washed in PBS by centrifugation. PrP levels were monitoredby
Western blot in total protein extracts. The molecular weight of PrP
corresponds tothe PK-resistant core, indicating the detection of the
exogenously added brain-derivedPrP. In this assay, PrPRES
oligomers are also observed (*). Actin levels were monitoredas
control.
(PDF)
Figure S4 Stable expression of prion mutants. Neuro2A
cells were transfected withindicated PrP expressing vectors
containing the 3F4 tag epitope, and then selectedwith G418 (1.3
mg/ml). The expression levels for each PrP version was assessed
overtime by Western blot analysis during early selection (~1 week,
upper panel) or afterstable selection (3 week, middle panel; 4
weeks, bottom panel). As loading control anon specific band is
presented from the 3F4 Western blot. Cells presented in the
rightpanel were used to the viability assays.
(PDF)
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